Research Briefings Built to Convert Newsletter Traffic

NNMT

5-Amino-1MQ inhibits nicotinamide N-methyltransferase to preserve NAD+

Intake + output

GLP-1s control caloric intake; 5-Amino-1MQ supports metabolic output

RUO

5-Amino-1MQ is a research chemical — not FDA-evaluated; research use only

ERRα/β/γ

Pan-ERR agonist — activates all three estrogen-related receptor isoforms

~400 nM

Approximate EC50 at each ERR isoform

RUO

Investigational — not FDA-approved; laboratory research use only

−27%

All-cause mortality vs control in a post-heart-attack meta-analysis (Mayo Clinic Proceedings, 2013)

37 RCTs

A 2020 meta-analysis found reduced body weight, BMI, and fat mass — strongest in overweight/obese adults

~1.33 kg

Average extra weight lost vs placebo in a separate 2016 meta-analysis

20% off

Memorial Day weekend — code MEMORIAL20 at checkout (ends Mon May 26)

~40%

Survodutide trial participants losing >20% baseline weight

MASH

Survodutide's distinguishing edge: histological liver-fibrosis improvement

1982

Approved as an immunomodulator in the former Soviet Union

T-cell

Primary mechanism: hematopoietic stem cell → mature T-lymphocyte differentiation

Cytokine

Re-examined during COVID-19 as a cytokine-storm modulator

Vascular

Targets the endothelium of white-fat blood supply, not the brain

Renal

Dose-dependent kidney toxicity is the headline safety signal

Primate

Strongest published data set is in obese rhesus macaque models

GVSWGLR

7-amino-acid sequence — a truncated, optimized spadin fragment

TREK-1

Highly selective inhibition of the two-pore-domain K+ channel

Hours

Onset of measurable antidepressant-like effects in preclinical models

5

New SKUs added to the catalog this week

$65–$110

Single-vial price range across the new peptide additions

1

First oral capsule version of an existing peptide vial

14–19

Peptides being restored to Category 1 status by HHS

23%

CagriSema 84-week weight loss in REDEFINE-4 Phase III

18.6%

Mazdutide placebo-adjusted weight reduction in MED Journal data

16.8%

Retatrutide weight-loss signal in Phase 3 topline data

10.7%

Amylin analog weight-loss signal with strong tolerability

92.2%

Fat-mass share of weight loss in Bimagrumab combination data